Liver transplant in patients with primary sclerosing cholangitis: A retrospective cohort from Northeastern Brazil

Table 2 Baseline and pretransplantation laboratory findings of patients with primary sclerosing cholangitis

Variables	n	Total1	Females (n = 141)	Males (n = 191)	P value2
ALP/RV1c	19	3.72 ± 3.02 (2.86)	2.23 ± 1.58 (1.89)	4.60 ± 3.37 (3.35)	0.045
GGT/RV1c	19	10 ± 9 (5)	5 ± 4 (4)	12 ± 9 (10)	0.210
AST/RV1c	23	5.86 ± 11.29 (3.00)	10.63 ± 18.86 (3.30)	3.31 ± 1.53 (2.86)	0.591
ALT/RV1c	23	3.28 ± 3.19 (2.46)	3.80 ± 5.18 (1.93)	3.01 ± 1.53 (2.75)	0.302
DB	24	7.4 ± 5.3 (5.9)	8.9 ± 5.2 (7.3)	6.8 ± 5.4 (5.9)	0.383
Antibody testing
ANA	20	3 (15%)	1 (17%)	2 (14%)	> 0.999
AASM	19	2 (11%)	1 (17%)	1 (7.7%)	> 0.999
AMA	19	0 (0%)	0 (0%)	0 (0%)
ANTI-SLA	11	0 (0%)	0 (0%)	0 (0%)
pANCA	12	4 (33%)	1 (33%)	3 (33%)	> 0.999
Pre-LTx lab results
ALT/RV	22	5.5 ± 8.8 (3.0)	6.2 ± 12.6 (2.1)	4.9 ± 4.1 (4.0)	0.138
AST/RV	23	16 ± 44 (5)	24 ± 66	9 ± 14 (5)	0.107
ALP/RV	22	2.79 ± 2.24 (1.84)	2.39 ± 2.37 (1.64)	3.06 ± 2.20 (2.54)	0.393
TB	22	15 ± 10 (11)	13 ± 10 (10)	17 ± 10 (12)	0.324
INR	27	2.08 ± 2.34 (1.51)	1.40 ± 0.32 (1.37)	2.54 ± 2.98 (1.71)	0.025
Creatinine	28	0.89 ± 0.80 (0.75)	0.94 ± 1.19 (0.52)	0.86 ± 0.34 (0.83)	0.143
MELD	27	22.4 ± 6.5 (22.0)	19.9 ± 8.1 (19.0)	24.1 ± 4.7 (23.5)	0.011

¹Range; mean ± SD (median); n (%).

²Wilcoxon rank sum exact test; Wilcoxon rank sum test; Fisher’s exact test; Pearson’s chi-squared test.

AASM: Anti-smooth muscle antibodies; ALP: Alkaline phosphatase; ALT: Alanine transaminase; AMA: Anti-mitochondrial antibody; ANA: Anti-nuclear antibodies; Anti-SLA: Anti-soluble liver antigen; AST: Aspartate transferase; DB: Direct bilirubin; GGT: γ-Glutamyl transferase; INR: International normalized ratio; MELD: Model for end-stage liver disease; pANCA: Perinuclear anti-neutrophil cytoplasmic antibody; RV: Reference value; TB: Total bilirubin; LTx: Liver transplantation.